Cross-Linking GPVI-Fc by Anti-Fc Antibodies Potentiates Its Inhibition of Atherosclerotic Plaque- and Collagen-Induced Platelet Activation

JACC: Basic to Translational Science

Volumn 1, Issue 3, 2016, Pages 131-142

  Jamasbi, Janina ^a   Megens, Remco T A ^a,b   Bianchini, Mariaelvy ^a   Uhland, Kerstin ^c   Münch, Götz ^c   Ungerer, Martin ^c   Sherman, Shachar ^d   Faussner, Alexander ^a   Brandl, Richard ^e   John, Christine ^f   Buchner, Johannes ^f   Weber, Christian ^a,b,g   Lorenz, Reinhard ^a   Elia, Natalie ^d   Siess, Wolfgang ^a,g  

^a UNIVERSITY OF MUNICH   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c ADVANCECOR GMBH   (Germany)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^e St Mary's Square Institute for Vascular Surgery and Phlebology ^*  (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

antithrombotic; atherothrombosis; glycoprotein VI; plaque rupture

Indexed keywords

EID: 85009360423     PISSN: 2452302X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacbts.2016.03.008     Document Type: Review

References (26)

1. 1 Fuster, V., Moreno, P.R., Fayad, Z.A., Corti, R., Badimon, J.J., Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 46 (2005), 937–954.
2. 2 Badimon, L., Vilahur, G., Thrombosis formation on atherosclerotic lesions and plaque rupture. J Intern Med 276 (2014), 618–632.
3. 3 van Zanten, G.H., de Graaf, S., Slootweg, P.J., et al. Increased platelet deposition on atherosclerotic coronary arteries. J Clin Invest 93 (1994), 615–632.
4. 4 Penz, S., Reininger, A.J., Brandl, R., et al. Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI. FASEB J 19 (2005), 898–909.
5. 5 Reininger, A.J., Bernlochner, I., Penz, S.M., et al. A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques. J Am Coll Cardiol 55 (2010), 1147–1158.
6. 6 Schulz, C., Penz, S., Hoffmann, C., et al. Platelet GPVI binds to collagenous structures in the core region of human atheromatous plaque and is critical for atheroprogression in vivo. Basic Res Cardiol 103 (2008), 356–367.
7. 7 Zahid, M., Mangin, P., Loyau, S., et al. The future of glycoprotein VI as an antithrombotic target. J Thromb Haemost 10 (2012), 2418–2427.
8. 8 Jung, S.M., Moroi, M., Soejima, K., et al. Constitutive dimerization of glycoprotein VI (GPVI) in resting platelets is essential for binding to collagen and activation in flowing blood. J Biol Chem 287 (2012), 30000–30013.
9. 9 Miura, Y., Takahashi, T., Jung, S.M., Moroi, M., Analysis of the interaction of platelet collagen receptor glycoprotein VI (GPVI) with collagen. A dimeric form of GPVI, but not the monomeric form, shows affinity to fibrous collagen. J Biol Chem 277 (2002), 46197–46204.
10. 10 Herr, A.B., Farndale, R.W., Structural insights into the interactions between platelet receptors and fibrillar collagen. J Biol Chem 284 (2009), 19781–19785.
11. 11 Smethurst, P.A., Joutsi-Korhonen, L., O'Connor, M.N., et al. Identification of the primary collagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody. Blood 103 (2004), 903–911.
12. 12 Massberg, S., Konrad, I., Bultmann, A., et al. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J 18 (2004), 397–399.
13. 13 Ungerer, M., Rosport, K., Bultmann, A., et al. Novel antiplatelet drug revacept (dimeric glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation 123 (2011), 1891–1899.
14. 14 Dutting, S., Bender, M., Nieswandt, B., Platelet GPVI: a target for antithrombotic therapy?!. Trends Pharmacol Sci 33 (2012), 583–590.
15. 15 Deckmyn, H., De Meyer, S.F., Broos, K., Vanhoorelbeke, K., Inhibitors of the interactions between collagen and its receptors on platelets. Handb Exp Pharmacol(210), 2012, 311–337.
16. 16 Jamasbi, J., Megens, R.T., Bianchini, M., et al. Differential inhibition of human atherosclerotic plaque-induced platelet activation by dimeric GPVI-Fc and anti-GPVI antibodies: Functional and imaging studies. J Am Coll Cardiol 65 (2015), 2404–2415.
17. 17 Brandl, R., Richter, T., Haug, K., Wilhelm, M.G., Maurer, P.C., Nathrath, W., Topographic analysis of proliferative activity in carotid endarterectomy specimens by immunocytochemical detection of the cell cycle-related antigen Ki-67. Circulation 96 (1997), 3360–3368.
18. 18 Bampalis, V.G., Brantl, S.A., Siess, W., Why and how to eliminate spontaneous platelet aggregation in blood measured by multiple electrode aggregometry. J Thromb Haemost 10 (2012), 1710–1714.
19. 19 Dwivedi, S., Pandey, D., Khandoga, A.L., Brandl, R., Siess, W., Rac1-mediated signaling plays a central role in secretion-dependent platelet aggregation in human blood stimulated by atherosclerotic plaque. J Transl Med, 8, 2010, 128.
20. 20 Elia, N., Ott, C., Lippincott-Schwartz, J., Incisive imaging and computation for cellular mysteries: lessons from abscission. Cell 155 (2013), 1220–1231.
21. 21 Cheruvu, P.K., Finn, A.V., Gardner, C., et al. Frequency and distribution of thin-cap fibroatheroma and ruptured plaques in human coronary arteries: a pathologic study. J Am Coll Cardiol 50 (2007), 940–949.
22. 22 Megens, R.T., oude Egbrink, M.G., Merkx, M., Slaaf, D.W., van Zandvoort, M.A., Two-photon microscopy on vital carotid arteries: imaging the relationship between collagen and inflammatory cells in atherosclerotic plaques. J Biomed Opt, 13, 2008, 044022.
23. 23 Kundu, S.K., Heilmann, E.J., Sio, R., Garcia, C., Davidson, R.M., Ostgaard, R.A., Description of an in vitro platelet function analyzer—PFA-100. Semin Thromb Hemost 21:Suppl 2 (1995), 106–112.
24. 24 Paniccia, R., Priora, R., Liotta, A.A., Abbate, R., Platelet function tests: a comparative review. Vasc Health Risk Manag 11 (2015), 133–148.
25. 25 Arthur, J.F., Dunkley, S., Andrews, R.K., Platelet glycoprotein VI-related clinical defects. Br J Haematol 139 (2007), 363–372.
26. 26 Deyev, S.M., Lebedenko, E.N., Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design. Bioessays 30 (2008), 904–918.